Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-64264681 |
Synonyms | |
Therapy Description |
JNJ-64264681 is a BTK inhibitor that blocks signaling through the BCR signaling pathway, potentially resulting in growth inhibition of tumor cells over expressing BTK (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-64264681 | JNJ 64264681|JNJ64264681 | BTK inhibitor 37 | JNJ-64264681 is a BTK inhibitor that blocks signaling through the BCR signaling pathway, potentially resulting in growth inhibition of tumor cells over expressing BTK (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04210219 | Phase I | JNJ-64264681 | A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia | Active, not recruiting | USA | POL | GBR | 4 |